Современные стратегии профилактики рака желудка - Журнал Терапевтический архив №12 Vario 2024

Современные стратегии профилактики рака желудка

Бордин Д.С., Никольская К.А., Чеботарева М.В., Хатьков И.Е. Современные стратегии профилактики рака желудка. Терапевтический архив. 2024;96(12):1115–1120. DOI: 10.26442/00403660.2024.12.203080

© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.

________________________________________________

Bordin DS, Nikolskaya KA, Chebotareva MV, Khatkov IE. Modern strategies for the gastric cancer prevention. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(12):1115–1120. DOI: 10.26442/00403660.2024.12.203080

Читать PDF

Аннотация

Рак желудка (РЖ) входит в пятерку лидеров в структуре заболеваемости и смертности среди онкологических заболеваний в Российской Федерации и в мире. В настоящее время наблюдается уменьшение заболеваемости РЖ, что связывают со снижением распространенности инфекции Helicobacter pylori. Однако в связи с изменением структуры населения, увеличением продолжительности жизни ожидается, что абсолютное число случаев РЖ и смертность увеличатся. РЖ является следствием длительного течения хронического гастрита. Как минимум 90% случаев РЖ обусловлены H. pylori. Снижение заболеваемости и смертности от РЖ достижимо при разумном сочетании 2 стратегий: первичной профилактики, основанной на выявлении и эрадикации H. pylori, и вторичной профилактики, которая базируется на эндоскопическом скрининге раннего РЖ и формировании групп высокого риска развития рака и их последующего эндоскопического наблюдения.

Ключевые слова: рак желудка, первичная профилактика рака желудка, Helicobacter pylori, эндоскопический скрининг

________________________________________________

Gastric cancer (GC) is one of the top five cancer morbidity and mortality rates in the Russian Federation and worldwide. Currently, there is a decrease in gastric cancer incidence, which is associated with a decrease in the prevalence of Helicobacter pylori infection. However, due to changes in the population structure and increased life expectancy, the absolute number of gastric cancer cases and mortality are expected to increase. GC is a consequence of long-term chronic gastritis. At least 90% of gastric cancers are caused by H. pylori. Reducing the incidence and mortality from GC is achievable with a reasonable combination of 2 strategies: primary prevention based on the detection and eradication of H. pylori, and secondary prevention, which is based on endoscopic screening of early GC and the formation of high-risk groups for cancer development and their subsequent endoscopic observation.

Keywords: gastric cancer, primary prevention of gastric cancer, Helicobacter pylori, endoscopic screening

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Хатьков И.Е., Абдулхаков С.Р., Алексеенко С.А., и др. Российский консенсус по профилактике, диагностике и лечению рака желудка. Злокачественные опухоли. 2023;13(2):56-68 [Khatkov IE, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on prevention, diagnosis and treatment of gastric cancer. Malignant Tumours. 2023;13(2):56-68 (in Russian)]. DOI:10.18027/2224-5057-2023-13-2-4
2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. Available at: https://gco.iarc.who.int/today. Accessed: 13.10.2024.
3. Злокачественные новообразования в России в 2023 г. (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024 [Zlokachestvennye novoobrazovaniia v Rossii v 2023 g. (zabolevaemost' i smertnost') / pod red. AD Kaprina, VV Starinskogo, GV Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2024 (in Russian)].
4. Состояние онкологической помощи населению России в 2023 г. / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2023 g. / pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2024 (in Russian)].
5. Huang RJ, Epplein M, Hamashima C, et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol.
2022;20(10):2218-28.e2. DOI:10.1016/j.cgh.2021.09.039
6. Leja M. Where are we with gastric cancer screening in Europe in 2024? Gut. 2024;73(12):2074-82. DOI:10.1136/gutjnl-2024-332705
7. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404. DOI:10.1016/j.eclinm.2022.101404
8. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. DOI:10.1136/gutjnl-2022-327745
9. Gullo I, Grillo F, Mastracci L, et al. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica. 2020;112(3):166-85. DOI:10.32074/1591-951X-166
10. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024;73(3):407-41. DOI:10.1136/gutjnl-2023-331164
11. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-2. DOI:10.1053/j.gastro.2017.04.022
12. Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553-64. DOI:10.1016/S2468-1253(23)00070-5
13. Chen YC, Malfertheiner P, Yu HT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605-19. DOI:10.1053/j.gastro.2023.12.022
14. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI:10.1111/hel.12924
15. Бакулина Н.В., Тихонов С.В., Савилова И.В., и др. Динамика распространенности инфекции Helicobacter pylori с 2015 по 2023 годы. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2023;15(3):41-51 [Bakulina NV, Tikhonov SV, Savilova IV, et al. Dynamics of the prevalence of Helicobacter pylori infection from 2015 to 2023. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2023;15(3):41-51 (in Russian)]. DOI:10.17816/mechnikov623259
16. Бордин Д.С., Кузнецова Е.С., Стаувер Е.Е., и др. Эпидемиология инфекции Helicobacter pylori в Российской Федерации с 1990 по 2023 г.: систематический обзор. РМЖ. Медицинское обозрение. 2024;8(5):260-7 [Bordin DS, Kuznetsova ES, Stauver EE, et al. Epidemiology of Helicobacter pylori infection in the Russian Federation from 1990 to 2023: a systematic review. Russian Medical Inquiry. 2024;8(5):260-7 (in Russian)]. DOI:10.32364/2587-6821-2024-8-5-3
17. Bordin D, Livzan M. History of chronic gastritis: How our perceptions have changed. World J Gastroenterol. 2024;30(13):1851-88. DOI:10.3748/wjg.v30.i13.1851
18. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-60.
19. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-9. DOI:10.1056/NEJMoa001999
20. Leja M, You W, Camargo MC, Saito H. Implementation of gastric cancer screening – the global experience. Best Pract Res Clin Gastroenterol. 2014;28(6):1093-0. DOI:10.1016/j.bpg.2014.09.005
21. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435-45. DOI:10.1007/s10120-018-0876-0
22. Ивашкин В.Т., Ульянин А.И., Маев И.В., и др. Современные подходы к проведению эрадикационной терапии H. pylori у взрослых (обзор литературы и резолюция Экспертного совета). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):7-19 [Ivashkin VТ, Ulyanin AI, Mayev IV, et al. Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):7-19 (in Russian)]. DOI:10.22416/1382-4376-2022-32-6-7-19
23. Ивашкин В.Т., Лапина Т.Л., Маев И.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93 [Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian)]. DOI:10.22416/1382-4376-2022-32-6-72-93
24. McNicholl AG, O'Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019;24(5):e12630. DOI:10.1111/hel.12630
25. Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. DOI:10.1136/gutjnl-2020-321372
26. Jonaitis P, Nyssen OP, Saracino IM, et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023;13(1):17235. DOI:10.1038/s41598-023-43287-4
27. Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024;119(4):646-54. DOI:10.14309/ajg.0000000000002600
28. Pabón-Carrasco M, Keco-Huerga A, Castro-Fernández M, et al. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(1):122-38. DOI:10.1002/ueg2.12476
29. Huguet JM, Ferrer-Barceló L, Suárez P, et al. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(6):691-704. DOI:10.1002/ueg2.12569
30. Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г., и др. Европейский регистр Helicobacter pylori (Hp-EuReg): как изменилась клиническая практика в России с 2013 по 2018 г. Терапевтический архив. 2019;91(2):16-24 [Bordin DS, Embutnieks YV, Vologzhanina LG, et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):16-24 (in Russian)]. DOI:10.26442/00403660.2019.02.000156
31. Бордин Д.С., Войнован И.Н., Эмбутниекс Ю.В., и др. Европейский регистр Helicobacter pylori (Hp-EuReg) как инструмент для оценки и улучшения клинической практики в Москве. Терапевтический архив. 2020;92(2):12-8 [Bordin DS, Voynovan IN, Embutnieks YV, et al. European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):12-8 (in Russian)]. DOI:10.26442/00403660.2020.02.000567
32. Абдулхаков С.Р., Бордин Д.С., Абдулхаков Р.А., и др. Европейский регистр ведения инфекции Helicobacter pylori: особенности диагностики и лечения в Казани. Терапевтический архив. 2020;92(8):52-9 [Abdulkhakov SR, Bordin DS, Abdulkhakov RA, et al. European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(8):52-9 (in Russian)]. DOI:10.26442/00403660.2020.08.000758
33. Бордин Д.С. Ошибки диагностики и лечения инфекции Helicobacter pylori: в преддверии новых согласительных документов. Экспериментальная и клиническая гастроэнтерология. 2021;(9):5-14 [Bordin DS. Errors in the diagnosis and treatment of Helicobacter pylori infection: in anticipation of new conciliation documents. Experimental and Clinical Gastroenterology. 2021;(9):5-14 (in Russian)]. DOI:10.31146/1682-8658-ecg-193-9-5-14
34. Bodunova N, Tsapkova L, Polyakova V, et al. Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Curr Issues Mol Biol. 2024;46(7):6665-64. DOI:10.3390/cimb46070397
35. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-88. DOI:10.1055/a-0859-1883
36. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36(3):228-33. DOI:10.1016/j.humpath.2004.12.008
37. Khomeriki SG, Bordin DS, Khomeriki NM, et al. The Impact of the Angulus Biopsy on the Detection of Staging and the Grading of Chronic Gastritis. Diagnostics (Basel). 2023;13(18). DOI:10.3390/diagnostics13182928
38. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152(6):1319-38.e7. DOI:10.1053/j.gastro.2017.01.029
39. Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol. 2020;35(9):1495-502. DOI:10.1111/jgh.15037
40. Syrjänen K, Eskelinen M, Peetsalu A, et al. GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review. Anticancer Res. 2019;39(3):1091-104. DOI:10.21873/anticanres.13218
41. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology.
2021;161(4):1325-32.e7. DOI:10.1053/j.gastro.2021.06.078
42. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels – The ABC Method. Digestion. 2016;93(1):13-8. DOI:10.1159/000441742
43. Kowada A. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening. Dig Dis Sci. 2023;68(5):1735-76.
DOI:10.1007/s10620-022-07795-z
44. Bordin DS, Livzan MA, Gaus OV, et al. Drug-Associated Gastropathy: Diagnostic Criteria. Diagnostics (Basel). 2023;13(13). DOI:10.3390/diagnostics13132220
45. Бордин Д.С., Ливзан М.А., Осипенко М.Ф., и др. Ключевые положения консенсуса Маастрихт VI. Экспериментальная и клиническая гастроэнтерология. 2022;(9):5-21 [Bordin DS, Livzan MA, Osipenko MF, et al. The key statements of the Maastricht VI consensus. Experimental and Clinical Gastroenterology. 2022;(9):5-21 (in Russian)]. DOI:10.31146/1682-8658-ecg-205-9-5-21

________________________________________________

1. Khatkov IE, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on prevention, diagnosis and treatment of gastric cancer. Malignant Tumours. 2023;13(2):56-68 (in Russian). DOI:10.18027/2224-5057-2023-13-2-4
2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. Available at: https://gco.iarc.who.int/today. Accessed: 13.10.2024.
3. Zlokachestvennye novoobrazovaniia v Rossii v 2023 g. (zabolevaemost' i smertnost') / pod red. AD Kaprina, VV Starinskogo, GV Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2024 (in Russian).
4. Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2023 g. / pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2024 (in Russian).
5. Huang RJ, Epplein M, Hamashima C, et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol.
2022;20(10):2218-28.e2. DOI:10.1016/j.cgh.2021.09.039
6. Leja M. Where are we with gastric cancer screening in Europe in 2024? Gut. 2024;73(12):2074-82. DOI:10.1136/gutjnl-2024-332705
7. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404. DOI:10.1016/j.eclinm.2022.101404
8. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. DOI:10.1136/gutjnl-2022-327745
9. Gullo I, Grillo F, Mastracci L, et al. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica. 2020;112(3):166-85. DOI:10.32074/1591-951X-166
10. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024;73(3):407-41. DOI:10.1136/gutjnl-2023-331164
11. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-2. DOI:10.1053/j.gastro.2017.04.022
12. Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553-64. DOI:10.1016/S2468-1253(23)00070-5
13. Chen YC, Malfertheiner P, Yu HT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605-19. DOI:10.1053/j.gastro.2023.12.022
14. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI:10.1111/hel.12924
15. Bakulina NV, Tikhonov SV, Savilova IV, et al. Dynamics of the prevalence of Helicobacter pylori infection from 2015 to 2023. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2023;15(3):41-51 (in Russian). DOI:10.17816/mechnikov623259
16. Bordin DS, Kuznetsova ES, Stauver EE, et al. Epidemiology of Helicobacter pylori infection in the Russian Federation from 1990 to 2023: a systematic review. Russian Medical Inquiry. 2024;8(5):260-7 (in Russian). DOI:10.32364/2587-6821-2024-8-5-3
17. Bordin D, Livzan M. History of chronic gastritis: How our perceptions have changed. World J Gastroenterol. 2024;30(13):1851-88. DOI:10.3748/wjg.v30.i13.1851
18. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-60.
19. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-9. DOI:10.1056/NEJMoa001999
20. Leja M, You W, Camargo MC, Saito H. Implementation of gastric cancer screening – the global experience. Best Pract Res Clin Gastroenterol. 2014;28(6):1093-0. DOI:10.1016/j.bpg.2014.09.005
21. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435-45. DOI:10.1007/s10120-018-0876-0
22. Ivashkin VТ, Ulyanin AI, Mayev IV, et al. Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):7-19 (in Russian). DOI:10.22416/1382-4376-2022-32-6-7-19
23. Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian). DOI:10.22416/1382-4376-2022-32-6-72-93
24. McNicholl AG, O'Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019;24(5):e12630. DOI:10.1111/hel.12630
25. Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. DOI:10.1136/gutjnl-2020-321372
26. Jonaitis P, Nyssen OP, Saracino IM, et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023;13(1):17235. DOI:10.1038/s41598-023-43287-4
27. Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024;119(4):646-54. DOI:10.14309/ajg.0000000000002600
28. Pabón-Carrasco M, Keco-Huerga A, Castro-Fernández M, et al. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(1):122-38. DOI:10.1002/ueg2.12476
29. Huguet JM, Ferrer-Barceló L, Suárez P, et al. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(6):691-704. DOI:10.1002/ueg2.12569
30. Bordin DS, Embutnieks YV, Vologzhanina LG, et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):16-24 (in Russian). DOI:10.26442/00403660.2019.02.000156
31. Bordin DS, Voynovan IN, Embutnieks YV, et al. European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):12-8 (in Russian). DOI:10.26442/00403660.2020.02.000567
32. Abdulkhakov SR, Bordin DS, Abdulkhakov RA, et al. European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(8):52-9 (in Russian). DOI:10.26442/00403660.2020.08.000758
33. Bordin DS. Errors in the diagnosis and treatment of Helicobacter pylori infection: in anticipation of new conciliation documents. Experimental and Clinical Gastroenterology.
2021;(9):5-14 (in Russian). DOI:10.31146/1682-8658-ecg-193-9-5-14
34. Bodunova N, Tsapkova L, Polyakova V, et al. Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Curr Issues Mol Biol. 2024;46(7):6665-64. DOI:10.3390/cimb46070397
35. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-88. DOI:10.1055/a-0859-1883
36. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36(3):228-33. DOI:10.1016/j.humpath.2004.12.008
37. Khomeriki SG, Bordin DS, Khomeriki NM, et al. The Impact of the Angulus Biopsy on the Detection of Staging and the Grading of Chronic Gastritis. Diagnostics (Basel). 2023;13(18). DOI:10.3390/diagnostics13182928
38. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152(6):1319-38.e7. DOI:10.1053/j.gastro.2017.01.029
39. Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol. 2020;35(9):1495-502. DOI:10.1111/jgh.15037
40. Syrjänen K, Eskelinen M, Peetsalu A, et al. GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review. Anticancer Res. 2019;39(3):1091-104. DOI:10.21873/anticanres.13218
41. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology.
2021;161(4):1325-32.e7. DOI:10.1053/j.gastro.2021.06.078
42. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels – The ABC Method. Digestion. 2016;93(1):13-8. DOI:10.1159/000441742
43. Kowada A. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening. Dig Dis Sci. 2023;68(5):1735-76.
DOI:10.1007/s10620-022-07795-z
44. Bordin DS, Livzan MA, Gaus OV, et al. Drug-Associated Gastropathy: Diagnostic Criteria. Diagnostics (Basel). 2023;13(13). DOI:10.3390/diagnostics13132220
45. Bordin DS, Livzan MA, Osipenko MF, et al. The key statements of the Maastricht VI consensus. Experimental and Clinical Gastroenterology. 2022;(9):5-21 (in Russian). DOI:10.31146/1682-8658-ecg-205-9-5-21

Авторы

Д.С. Бордин*^1–3, К.А. Никольская^1,4, М.В. Чеботарева^1,4, И.Е. Хатьков^1,2

¹ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
²ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия;
³ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
⁴ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» Департамента здравоохранения г. Москвы, Москва, Россия
*dbordin@mail.ru

________________________________________________

Dmitry S. Bordin*^1–3, Karine A. Nikolskaya^1,4, Margarita V. Chebotareva^1,4, Igor E. Khatkov^1,2

¹Loginov Moscow Clinical Scientific Center, Moscow, Russia;
²Russian University of Medicine, Moscow, Russia;
³Tver State Medical University, Tver, Russia;
⁴Research Institute of Public Health Organization and Medical Management, Moscow, Russia
*dbordin@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.